
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Barcelona - Ebastine, a second-generation antihistamine currently marketed in Europe and Japan, offers many advantages as a treatment for mild to moderate alopecia areata, according to Yusuke Yoshizawa, M.D., assistant professor of dermatology, Nippon Medical School, Tokyo.






